source
- China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slumpBiotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
- FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are rankedThe Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…